眼内液分子参与高度近视及其眼底病变发病机制的研究进展  

A review of advances in intraocular fluid detection for high myopia and its relevant fundus diseases

作　　者：刘晋星 周国宏[2] 张潇丹 Liu Jinxing;Zhou Guohong;Zhang Xiaodan(The First School of Clinical Medicine,Shanxi Medical University,Taiyuan 030001,China;Eye Hospital of Shanxi Province,Taiyuan 030002,China)

机构地区：[1]山西医科大学第一临床医学院,太原030001 [2]山西省眼科医院,太原030002

出　　处：《中华眼底病杂志》2022年第9期784-788,共5页Chinese Journal of Ocular Fundus Diseases

基　　金：山西省卫生厅"四个一批"重点项目(2020RC22);山西省科技厅重点研发计划(社发领域)一般项目(201903D321117)。

摘　　要：高度近视(HM)引起的眼底病变常导致不可逆的视力损害甚至失明。但HM及其眼底病变发病机制尚不明确,微量样本的眼内液检测技术为眼底病变的早期诊断、监测、干预带来了新的前景。与HM相关的分子种类繁多、功能多样,分子间相互作用交错,分子机制复杂。随着微量眼内液检测技术的发展,在逐步揭示各分子在HM发病机制中作用的同时,有望未来成功辅助临床工作,提供近视发生进展的前哨标志及早期干预的靶点,或可在分子水平针对发病机制为HM眼底病变提供靶向治疗的新选择,未来有望为HM患者提供更准确有效的治疗。The fundus lesions caused by high myopia(HM)often lead to irreversible visual impairment or even blindness.However,the pathogenesis of HM and its fundus lesions is still unclear,the intraocular fluid detection technology of micro samples has brought new prospects for the early diagnosis,monitoring and intervention of the fundus lesions.The molecules associated with HM are various and functionally diverse,intermolecular interactions are staggered and the specific mechanism is complex.With the development of intraocular fluid detection technology,while gradually revealing the role of each molecule in the pathogenesis of HM,it is expected to successfully assist clinical work in the future,providing outpost markers for the progress of myopia and targets for early intervention,or providing a new therapy choice for HM fundus lesions at the molecular level targeting pathogenesis,which is expected to provide more accurate and effective treatment for HM patients in the future.

关 键 词：近视 退行性 眼房水 蛋白质类 细胞因子类 基质金属蛋白酶2 纤维蛋白溶酶 综述 

分 类 号：R778.11[医药卫生—眼科]